CAP 2008.

Methods	6‐Week wash‐out period 26‐Week multi‐centre prospective randomised double‐blind double‐dummy design
Participants	340 men and women aged < 80 years with documented CAD; low‐grade inflammation, LDL‐C 1.29 to 3.87 mmol/L (50‐150 mg/dL), TG ≤ 4.56 mmol/L (400 mg/dL) 170 received 10 mg/d, 169 received 80 mg/d Exclusion criteria: presence of secondary hyperlipidaemia or type 1 diabetes mellitus or type 2 with insulin therapy, inadequately controlled diabetes mellitus, alcohol or drug abuse, inadequate compliance, progressive or life‐threatening disease with life expectancy < 1 year, statin intolerance, active hepatic disease or hepatic dysfunction, use of a potent cytochrome P45 3A4 inhibitor, women who were pregnant or breastfeeding Atorvastatin 10 mg/d baseline TC: 5.41 mmol/L (209 mg/dL) Atorvastatin 10 mg/d baseline LDL‐C: 3.26 mmol/L (126 mg/dL) Atorvastatin 10 mg/d baseline HDL‐C: 1.24 mmol/L (48 mg/dL) Atorvastatin 10 mg/d baseline TG: 2.05 mmol/L (182 mg/dL) Atorvastatin 80 mg/d baseline TC: 5.34 mmol/L (206 mg/dL) Atorvastatin 80 mg/d baseline LDL‐C: 3.26 mmol/L (126 mg/dL) Atorvastatin 80 mg/d baseline HDL‐C: 1.24 mmol/L (48 mg/dL) Atorvastatin 80 mg/d baseline TG: 1.85 mmol/L (164 mg/dL)
Interventions	Atorvastatin 10 mg/d Atorvastatin 80 mg/d
Outcomes	Per cent change from baseline at 5 weeks of serum TC, LDL‐C, HDL‐C and TG
Notes	SDs were imputed
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of random sequence generation is not applicable
Allocation concealment (selection bias)	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, assessment of allocation concealment is not applicable
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Atorvastatin 10 mg/d; intervention was analysed, and as no placebo group was included for comparison, blinding status is not applicable
Incomplete outcome data (attrition bias) All outcomes	Low risk	Atorvastatin 10 mg/d: All 170 were included in the analysis Atorvastatin 80 mg/d: 1/170 was not included in the ITT analysis because of lack of post‐baseline data 0.3% of participants were excluded from the efficacy analysis
Selective reporting (reporting bias)	Low risk	All lipid parameters were measured
Other bias	High risk	Pfizer funded the study; data may support bias for atorvastatin